Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation
PARIS, Ontario, May 14, 2018 (GLOBE NEWSWIRE) — Emblem Corp. (TSX-V:EMC) (TSX-V:EMC.WT) (“Emblem” or the “Company”) and Canntab Therapeutics Limited (CSE:PILL) (“Canntab”) are pleased to announce the receipt of...